Revolutionary cancer therapy: Menarini secures groundbreaking license!

Revolutionary cancer therapy: Menarini secures groundbreaking license!

The Menarini Group has announced a groundbreaking development in the field of oncology. In an exclusive agreement with Insilico Medicine, a company specializing in generative artificial intelligence, Menarini has gained global rights to develop a promising small molecule drug. This targets a variety of solid tumors and could offer new therapy options for cancer patients. Loud Menarini The contract will include an upfront payment of US$20 million, with the total value of the agreement being over US$550 million, including additional payment terms.

Innovative cancer therapies on the horizon

This new active ingredient is based on Insilico's advanced technologies that enable drug development using generative AI. It has demonstrated impressive anti-tumor activity in preclinical studies. “We are excited about this second collaboration with Insilico Medicine,” said Elcin Barker Ergun, CEO of Menarini Group. “This compound will help us move into areas of high unmet need and create new treatment options for cancer patients,” he added. This isn't the first time Menarini and Insilico have worked together; A similar license agreement was concluded in January 2024 for the promising active ingredient MEN2312, which is also progressing into the clinical phase.

The Menarini Group is an international pharmaceutical company with annual sales of over $4.7 billion and over 17,000 employees. The company focuses on areas of high unmet need, particularly in oncology, pulmonology and diabetology. Insilico Medicine, on the other hand, uses AI technologies to develop innovative solutions for drug discovery. This collaboration could not only significantly improve the treatment of cancer, but also represent a new approach to drug development, such as according to a report from OTS emerges.